

Sector Note

#### India

#### Underweight (no change)

#### **Highlighted Companies**

Astec Lifesciences Ltd

**REDUCE, TP Rs1073, Rs1703 close** We forecast revenue growth at a 13% CAGR and PAT at 14.9% CAGR over FY21-24F for Astec Lifesciences. The uncertainty to earnings is high as its only product class SBI triazole sales are

#### declining globally Heranba Industries Ltd

REDUCE, TP Rs436, Rs717 close

Lack of production capacity, slow-growing market, rising raw material prices and intense competition faced by global leaders are headwinds for Heranba.

#### UPL Limited

#### REDUCE, TP Rs754, Rs790 close

Weather, currency and supply chain risks are business risks of UPL (company has no control over them) which makes its earnings volatile. Lack of new products and stagnant-to-declining nature of its old products are long-term business risks.

#### **Summary Valuation Metrics**

P/E (x)	Mar22-F	Mar23-F	Mar24-F
Astec Lifesciences Ltd	56.65	42.54	33.74
Heranba Industries Ltd	22.27	24.66	24.73
UPL Limited	18.31	16.69	14.21
P/BV (x)	Mar22-F	Mar23-F	Mar24-F
Astec Lifesciences Ltd	8.45	6.69	5.37
Heranba Industries Ltd	4.39	3.74	3.26
UPL Limited	2.51	2.19	1.9
Dividend Yield	Mar22-F	Mar23-F	Mar24-F
Astec Lifesciences Ltd	0.11%	0.15%	0.18%
Heranba Industries Ltd	0.08%	0.07%	0.07%
UPL Limited	1.43%	1.57%	1.85%

## **Chemicals - Overall**

### Agrochemicals - Changing dynamics

- Success of diamide insecticides, pricing pressure on amino acid herbicides & regulatory issue with dithiocarbates fungicides - landscape is changing rapidly.
- Diamide insecticides are fast replacing pyrethroids. Please note that 80% of insecticides sales growth in last nine years has been driven by diamides.
- We downgrade UPL to REDUCE; maintain REDUCE on Astec Life Sciences, Heranba, India Pesticides and Dhanuka Agritech. Top picks - Rallis and Bayer.

#### Old success stories in agrochemicals are losing sheen

In past four years, amino acid-based herbicides (glyphosate and glufosinate) are facing headwinds. Glufosinate faces pricing pressure while in case of glyphosate it is regulatory action. Dithiocarbamate fungicides (primarily mancozeb) are also facing increased regulatory action because of its harmful impact on humans. Within insecticides, neonicotinoid (multiple Indian companies are present here), which is stagnant since the last decade, is also facing increased regulatory action. Diamides is the success story of last five years (primarily rynaxypyr or chlorantraniliprole), but Indian presence in this chemical class is limited to contract manufacturing. PI Industries as well as UPL do contract manufacturing of chlorantraniliprole for FMC. Access to new seed technology (particularly gene editing and GMO) is critical for success in coming decades. Unfortunately, none of the Indian companies are making any efforts to diversify. In this regard, we like Bayer and Rallis. We downgrade our rating on UPL to REDUCE, and retain REDUCE rating on Astec Life Sciences, Heranba, India Pesticides, and Dhanuka Agritech.

#### Multiple new chemical classes emerge with scant Indian presence

Multiple new classes of chemicals are emerging, but Indian companies lag across all agrochemicals development. In herbicides, it is PPO (last decade – 5.5% CAGR), HPPD (4.5% CAGR over CY12-20), and other ALS (2% CAGR over CY12-20). All these chemicals have scant presence of Indian companies. Similarly, among insecticides, its diamide (12% CAGR over CY12-20) and biologicals (5% CAGR over CY12-20). Indian companies like UPL and others are making some efforts in biologicals but their diamide presence is limited to doing contract manufacturing for FMC. Most Indian insecticide companies are in operating in the neonicotinoid class of chemicals which is facing increased regulatory action as well as sales stagnancy. In fungicides, SDHI strobilurin is fastest-growing. Indian presence in SDHI (succinate dehydrogenase inhibitor) is limited to making intermediaries for these chemicals (SRF does it). Arysta (part of UPL) also manufactures one chemical - carboxin - whose global sales fell at a 7% CAGR over CY12-20. Fastest- growing molecules in this segment are fluxapyroxad, benzovindiflupyr, bixafen, fluopyram, sedaxane and penflufen, which grew at 22%, 77%,11%, 34%, 23% and 34% CAGR, respectively, over CY12-20, witnessed scant Indian presence.

#### Analyst(s)



Satish KUMAR T (91) 22 4161 1562 E satish.kumar@incredcapital.com Shaily RUPARELIA T (91) 22 4161 1556 E shaily.ruparelia@incredcapital.com

	We have downgraded UPL to R s with ADD rating in our agroc		only
Sr No.	Name of the company	Target Price	Rating
1	Astec Lifesciences Ltd	REDUCE	1073
2	Bayer Cropscience Ltd	ADD	6621
3	Dhanuka Agritech Ltd	REDUCE	704
4	Heranba Industries Ltd	REDUCE	436
5	India Pesticides Ltd	REDUCE	287
6	Rallis India Ltd	ADD	355
7	UPL Limited	REDUCE	754
		SOURCES: INCRED RESEARCH,	COMPANY REPORTS

IMPORTANT DISCLOSURES, INCLUDING ANY REQUIRED RESEARCH CERTIFICATIONS, ARE PROVIDED AT THE END OF THIS REPORT. IF THIS REPORT IS DISTRIBUTED IN THE UNITED STATES IT IS DISTRIBUTED BY CGS-CIMB SECURITIES (USA), INC. AND IS CONSIDERED THIRD-PARTY AFFILIATED RESEARCH.




### Agrochemicals - Changing dynamics

Global agrochemicals market is in a flux. Increased regulatory oversight, changing weather patterns, and increased competitive pressure from the innovators is making life difficult for generic companies and their suppliers. The Covid-19 pandemic and increased supply chain disruption has only increased margin pressure for companies. We downgrade UPL to REDUCE and maintain REDUCE rating on Astec Lifesciences, Heranba and India Pesticides

#### Fungicides - hyper growth of mancozeb is over

In the past few years, many Indian companies' growth, including that of UPL, was driven by mancozeb. The success of mancozeb against Asian rust disease led to the growth in sales of mancozeb at a scorching pace. However, changing crop patterns and increased usage of other multi-site fungicides take market share away from mancozeb.

## Since past few years growth has been driven by old fungicides SDHI and strobulins ➤




#### Growth in dithiocarbamate was driven by mancozeb >

Dithiocarbamate fungicides are multi-site, non-systemic and non-selective products with contact and protective activity and are commonly known as EBDCs or ethylene bis dithiocarbamates. The products act via inhibition of fungal metabolism at many sites, as a result of which the risk of resistance or tolerance build-up is very low. They are used in a wide range of crop situations, mostly by foliar application, but also with some seed treatment usage. All the products in this segment are now off-patent and have commodity status, being manufactured by a number of companies around the world. In India, UPL is the major manufacturer of mancozeb. Apart from UPL, other companies like Coromandel international also make mancozeb.




### **InCred** Equities





## Mancozeb's success was driven by Asian rust impact on soybean in Brazil **>**




#### UPL got the lion's share in growing Brazil mancozeb market >


UPL got the lion's share in Brazil's growing market for mancozeb. As per IHSMARKIT, it had nearly 50% market share in Brazil's mancozeb market during CY20.



### **InCred** Equities



#### Strobilurin is another important chemical class in fungicides >



#### Strobilurin is a relatively recent chemical class >

Strobilurin was first introduced in 1996 with kresoxim-methyl from BASF, and closely followed by azoxystrobin from Zeneca (now Syngenta) in 1997. Since then, products from this group have rapidly gained market share in the fungicides segment due to their versatility, applications in a wide range of crop segments, broad spectrum of action, compatibility with other products, and low application rates.

Figure 10: Strobilurin is a relatively recent chemical class - apart from Rallis, no other Indian company has a significant presence in this category			
	Launch Date	Major Producers	
Azoxystrobin	1997	Syngenta, FMC, and Various Chinese Producers	
Pyraclostrobin	2002	BASF	
Trifloxystrobin	2000	Bayer	
Picoxystrobin	2001	Corteva	
Kresoxim-Methyl	1996	BASF, Adama, Rallis	
Fluoxastrobin	2004	Bayer	
Orysastrobin	2007	BASF	
Dimoxystrobin	2004	BASF	
Mandestrobin	2016	Sumitomo Chemicals	
Metominostrobin	2000	Sumitomo Chemicals	
Pyraoxystrobin	2009	Shenyang Research Institute	
Enestroburin	2006	Sinochem/ Shenyang Research Institute	
Coumoxystrobin	2010		
Fenamistrobin	2008		
		SOURCES: INCRED RESEARCH, IHSMARKIT	

### Strobilurin class of chemicals developing resistance, which is a major headwind ➤

Resistance now plays a significant role in development of the strobilurin market, initially in cereal segment, and now also in soybean. Powdery mildew resistance to kresoxim was reported relatively early after the product's introduction, and more recently septoria resistance to the group as a whole has been an issue. While most of the sales in cereals segment comes as a result of the greening impact and yield benefits that the products provide, the expenditure incurred by farmers for early season septoria control by other chemistries reportedly limits spending on later season strobilurin use, particularly in years of low cereal prices.



# With hardly any new molecules in the pipeline, manufacturers are increasingly selling their mixture with SBI triazoles and even dithiocarbamate >

Various producers are trying different chemical mixtures with strobilurin - mostly SBI triazoles are used and sometimes even dithiocarbamate is tried out.

- 1. In 2019, the UK-based agrochemicals company, Agform, launched its broadspectrum fungicide, Oxe (azoxystrobin), in the UK.
- 2. In 2019, Nufarm launched its systemic fungicide, Tamiz (azoxystrobin + tebuconazole), in Brazil, for the control of rust disease, cercospora spp such as leaf spot.
- 3. In 2019, FMC applied to the US EPA to register F4412-1 (fluindapyr 10.5% + azoxystrobin 15.7%) for use on maize, soybeans, sorghum, wheat, triticale, and barley.
- 4. In 2019, UPL launched its triple action fungicide, Tridium (azoxystrobin + mancozeb + tebuconazole), in Brazil.
- 5. In 2019, Syngenta introduced the fungicide, Orondis Flexi (oxathiapiprolin 15 g/litre + azoxystrobin 155 g/litre),
- In Feb 2020, Syngenta introduced the seed treatment, Vibrance RST (azoxystrobin + fludioxonil + metalalxyl-M + sedaxane), for use on rice in the US.
- 7. In Feb 2020, Syngenta debuted Oliva Top (azoxystrobin + difenoconazole), in Spain for olive groves, rice and covered and field fruit and vegetables.
- 8. In 2020, Syngenta launched three fungicides for US golf course turf including Posterity Forte (pydiflumetofen + azoxystrobin + propiconazole).
- 9. BASF's Obvious Plus seed treatment (fluxapyroxad, pyraclostrobin, thiophanate-methyl and metalalxyl) was launched in 2019.
- 10. In 2019, BASF launched Tessior (boscalid + pyraclostrobin), in Spain for the control of grapevine trunk disease.
- 11. In May 2020, BASF launched Melyra (mefentrifluconazole + pyraclostrobin), in China. This marked the first launch of a product containing mefentrifluconazole in the Asia Pacific region. Melyra is for professional tomato and grape growers, but the company is planning to expand the approved label to a wider array of crops, including apple and cucumber.
- 12. BASF received Canadian registration in 2021 for Veltyma (pyraclostrobin + mefentrifluconazole) for use on crops such as maize, potato, wheat and soybean. BASF also received Canadian registration for its seed treatment,
- 13. Vercoras (clothianidin + fluopyram + metalalxyl + fluxapyroxad + pyraclostrobin), for use on the company's genetically modified herbicide-tolerant canola. The product offers broad-spectrum control against seed and soil-borne diseases such as blackleg (leptosphaeria maculans) during critical early season infection, besides providing baseline protection against flea beetles (phyllotreta cruciferae).
- 14. BASF had plans to launch Ceriax Plus (pyraclostrobin + fluxapyroxad + epoxiconazole) in Russia in 2021.
- 15. BASF introduced Priaxor (fluxapyroxad + pyraclostrobin) in Spain in 2021 for the control of major foliar cereal diseases such as septoria spp, and leaf rust (puccinia triticina) on wheat, and brown rust (puccinia hordei) and ramularia leaf spot (ramularia collo-cygni) in barley. The product was launched for soybean in Argentina in 2020 for the control of Asian soybean rust (phakopsora pachyrhizi), brown spot, ring spot, frog eye spot and purple spot.
- 16. In 2017, Bayer gained approval for Fox-Xpro (bixafen + prothioconazole + trifloxystrobin) for use on cotton, barley, sunflower and soybean.
- Also in 2017, Bayer launched Cripton Xpro (bixafen + prothioconazole + trifloxystrobin), in Argentina for use in cereals and peanut and Luna Sensation (fluopyram + trifloxystrobin), and in Canada for use on stone fruit, root vegetables, cucurbit vegetables, leafy petiole vegetables, brassicas and hops.



- Bayer's Delaro Complete (fluopyram + prothioconazole + trifloxystrobin), received registration in eastern Canada in 2021 for use on maize, soybean and cereal crops. The product gained US EPA approval in 2020 for use on maize and soybean.
- 19. In 2017, DuPont launched Vessarya (picoxystrobin, benzovindiflupyr) in Brazil for use on cereals.
- 20. In Feb 2020, Corteva Agriscience trade-marked picoxystrobin as Onmira. It has been selected to give a consistent global brand to the Agrochemical intermediary in more than 15 picoxystrobin-based products, including Vassarya (picoxystrobin + Syngenta's benzovindiflupyr).
- 21. Corteva launched Viovan (picoxystrobin + prothioconazole) and Aproach Power (picoxystrobin + cyproconazole) in Brazil in 2021 for use on soybean.

### Strobulin or SDHI is not a multi-site fungicide but when mixed with SBI triazole its effectiveness goes up ➤

While Strobulin or SDHI is not a multi-site fungicide, but when is applied in a mixture with SBI triazole/ dithiocarbamate/ other azoles, its effectiveness goes up. SBI triazoles are also mixed with SDHI to increase their effectiveness.

### Ditheocarbamate fungicide like mancozeb has lots of controversies surrounding it ➤

Dithiocarbamate fungicide like mancozeb has loads of controversies surrounding it. There are many groups who argue that it is proven to be cancerous but it is still in use. We have listed research papers below that have arguments on both sides:

- 1. <u>Factcheck (Mostly False: "The pesticide mancozeb is a relatively harmless</u> <u>substance" – eufactcheck.eu</u>)
- Scandinavian Journal of Work, Environment & Health Indicators of mancozeb exposure in relation to thyroid cancer and neural tube... (sjweh.fi)
- 3. <u>Transplacental Carcinogenic Potential of the Carbamate Fungicide Mancozeb</u> (researchgate.net)
- 4. Federal Register :: Mancozeb; Pesticide Tolerances
- 5. Mancozeb OEHHA (ca.gov)
- 6. <u>Occupational Exposure to Pesticides With Occupational Sun Exposure</u> Increases the Risk for Cutaneous Melanoma.
- 7. <u>Mancozeb.pdf (ppqs.gov.in)</u>

# Controversy around dithiocarmate along with effectiveness of other fungicide formulation will keep mancozeb sales under check ➤

Naturally, we are not competent enough to pass a judgement on the toxicity of mancozeb, but there is enough noise on this matter which can keep the growth of mancozeb and dithiocarbamate fungicides under check.

#### SBI triazoles also face lots of regulatory action ➤

- 1. <u>Side effects of the sterol biosynthesis inhibitor fungicide, propiconazole, on a</u> <u>beneficial arbuscular mycorrhizal fungus</u>
- 2. International Symposium on Sterol Biosynthesis Inhibitors Pharmaceutical and Agrochemical Aspects on JSTOR
- 3. <u>JoF | Free Full-Text | Triazole-Resistance in Environmental Aspergillus</u> <u>fumigatus in Latin American and African Countries | HTML (mdpi.com)</u>



### SBI triazoles as well as dicarbamate usage will be limited going ahead ▶

It appears that SBI triazoles and dicarbamate usage will be limited going ahead as there are regulatory headwinds across the board for them. On the other hand, strobulin and SDHI are doing well. The future belongs to strobulin and SDHI. SBI triazoles and dicarbamates can, at best, be mixture partners, thus limiting their growth potential.


#### Change in crop pattern of soybean is limiting soybean rust ➤

Asian rust attacks on soybean crops, which take place between Apr-Sep, are much more accentuated. Farmers are advised in Brazil to limit the planting during this season, which is another limiting factor for dicarbamate group of fungicides.

#### Herbicides- there's price war as new products are rare

We haven't seen any significant new product development in this agrochemicals sub-section. Over the last 10 years, 18 new products have been introduced whose combined sales stood at US\$756m in CY20 or around 3% of overall sales. The amino acid-based herbicides still lead the pack (glyphosate and glufosinate) but most of the new products are in HPDD (4-hydroxyphenylpyruvate dioxygenase). Amino-based herbicides are facing regulatory action in many parts of the world which is limiting their usage/growth. Almost all successful products are now generic and so the selling point is the development of herbicide-tolerant seeds on which standalone generic agrochemical companies (without the ability to develop seeds) don't stand against big companies like Bayer/ Syngenta. Generic players like UPL will keep facing the price heat on the product side.

## Amino acid still remains the major product class in herbicides **>**




# However, amino acid blocker herbicide, particulary glyphosate, is facing multiple headwinds in the form of regulatory action in USA ➤

In USA, it is taking the shape of a class action suit which can result in multi-billion dollar losses for the parent company.



### InCred Equities



- In Feb 2019, a federal judge in the US state of California rejected Bayer legacy company Monsanto's bid to defend against hundreds of lawsuits In Mar 2019, a federal jury concluded that Monsanto's glyphosate was likely a substantial factor in causing a California man to develop cancer. In Mar 2019, a US federal jury ordered Bayer legacy company Monsanto to pay this California man more than US\$80m in damages, concluding that the company had failed to warn him of the potential cancer risk from Roundup.
- 2. As on11 Jul 2019, Bayer witnessed an increase of over a third in the number of plaintiffs seeking damages for exposure to glyphosate. The number of plaintiffs reached 18,400. In Nov 2019, Bayer confirmed the scale of the reported surge in US lawsuits from plaintiffs seeking damages.
- 3. As on 11 Oct 2020, the number of lawsuits filed stood at approximately 42,700. In Mar 2020, the US EPA was hit with a pair of lawsuits challenging its decision to re-register the herbicide, glyphosate. Filed by environmentalists and farmworker advocates, the complaints alleged that the agency's review of the widely used herbicide had violated federal pesticide law as well as the Endangered Species Act.
- 4. In Apr 2020, Bayer settled a class action lawsuit contesting the marketing of Roundup. The company agreed to a US\$39.6m nationwide settlement regarding the claims, which includes the removal of certain statements from product labels. By 14 Apr 2020, Bayer announced that lawsuits involving approximately 52,500 plaintiffs had been served in the US in connection with glyphosate-based Roundup herbicide products.
- In Jun 2020, Bayer announced it had settled several major legacy Monsanto litigations out-of-court including with tens of thousands of plaintiffs for the alleged link between Monsanto's Roundup and cancer. Pending agreement of the courts, the Roundup settlements could total between US\$10.1bn -US\$10.9bn.
- 6. The headline Roundup deal is among a series of agreements that will substantially resolve major outstanding Monsanto litigation, Bayer stated. They include the US Roundup litigation, as well as the dicamba drift, for which it has settled for US\$400m, and polychlorinated biphenyl (PCB)-contaminated water litigations with payments totalling US\$820m. The combined settlements could total US\$12bn. The glyphosate litigation settlement covers about three-quarters of the some 125,000 filed and unfiled claims, around 90,000 litigants.
- 7. On 20 Jul 2020, a California appeals court upheld a state jury verdict that found Bayer-owned Monsanto failed to warn consumers of the potential cancer risks from Roundup. However, the court did reject the plaintiffs request




to reinstate the original US\$289m verdict, instead reducing the damages from US\$78m to US\$20.4m.


8. In Sep 2020, US environmentalist organisation, Center for Biological Diversity (CBD), filed a lawsuit against the USDA, alleging that the department worked on behalf of Bayer to influence Thailand in reversing a 2019 ban on the herbicide, glyphosate. The lawsuit, filed on 16 Sep at the US District Court for the District of Columbia, seeks the release of records concerning USDA's interaction with Bayer and other companies that stood to benefit from Thailand scrapping its plan.

#### Glufosinate can benefit from the predicament of glyphosate but Indian company UPL lacks the seed to go with glufosinate ➤

The increased regulatory and legal pressure on glyphosate is good news for glufosinate. However as always, the key for selling any herbicide is the development of resistant seeds. UPL and other generic players have no advantage here. The margins on glufosinate are likely to keep coming down over the period. Glufosinate-tolerant seeds are sold under Liberty ready brand by Bayer.


## ALS-sulfonylurea, ALS-other ALS and ALS-imidazolinone are other prominent groups of old herbicides **>**







## Only two new herbicides have been launched in ALS group over the last decade >




Name	CY20	Launch date
Imazaquin	410.00	2009
Imazapyr	395.00	1991
Tritosulfuron	385.00	1997
Trifloxysulfuron	230.00	2000
Ethoxysulfuron	225.00	2007
Pyroxsulam	222.00	1985
Imazamox	205.00	1984
Pyribenzoxim	205.00	2005
Orthosulfamuron	180.00	2002
Iodosulfuron	165.00	1987
Azimsulfuron	150.00	2001
Tribenuron	144.00	1985
Foramsulfuron	144.00	1991
Flazasulfuron	133.00	1998
Prosulfuron	113.00	1998
Pyrazosulfuron	106.00	1997
Penoxsulam	102.00	1985
Florasulam	101.00	1984
Metsulfuron	95.00	1985
Pyriminobac-Methyl	88.00	2002

## UPL is not present in any of high-growth ALS chemicals space $\rightarrow$

UPL sells pyrazusulfuron, metsulfuron, triasulfuron and sulfosulfuron. The growth of these four chemicals since last nine years has been at 3%, 5%, -2% and -8% CAGR, respectively.

### Like prices of most herbicides, prices of ALS-based herbicide are also falling ➤





## HPPD is a high growth area of hebicides but Indian companies have a negligible presence in this area **>**





Figure 19: Despite being generic players, most Indian companies are not present in these herbicides

Chemical Name	Launch date
Mesotrione	2001
Tembotrione	2007
Isoxaflutole	1996
Topramezone	2006
Pyrasulfotole	2007
Bicyclopyrone	2015
Benzobicyclon	2001
Tolpyralate	2017
Tefuryltrione	2008
Sulcotrione	1990
Pyrazolynate	1979
Fenquinotrione	2018
Fenpyrazone	2020
Tripyrasulfone	2020
Benzofenap	1990
Lancotrione-sodium	2019
Pyrazoxyfen	1985

SOURCES: INCRED RESEARCH, IHSMARKIT

#### HPPD prices are also on the decline >




## **PPO** (protoporphyrinogen oxidase) group of herbicides is another growth area for agrochemical majors $\blacktriangleright$

There are two group of herbicides in the broader class PPO- diphenyl ethers and PPO others. The overall growth rate in this segment has been  $\sim$ 4% CAGR over CY12-20.


- Diphenyl ether herbicides act via inhibition of protoporphyrinogen oxidase (PPO), an enzyme involved in chlorophyll biosynthesis. Most of the herbicides in this class are active following post-emergence application for the control of broadleaf weeds across a wide range of crop usages.
- 2. In broad PPO others segment, multiple research and development or R&D efforts are going on, but unfortunately Indian companies are nowhere to be seen.



### InCred Equities



The presence of a major Indian company like UPL is limited to Acifluorfen, which is soybean and peanut herbicide. Please note that acifluorfen sales have declined at a 8% CAGR over 2015-20.



#### Pricing is still volatile for this group of herbicides >

### There is some innovation in PPO group, but none of the Indian names are present in this group ➤

- 2021: Irifludimoxazin (BAS 850 H/tirexor) from BASF is a PPO inhibitor under development for usage in maize, soybean, citrus, pome and others against a range of ryegrass, broad-leaved, and resistant weeds including key species such as pigweed (amaranthus spp.) and ragweed (ambrosia spp.). The ai (agrochemical intermediary) is described as having the potential to be used in a synergistic fashion with saflufenacil. The ai also reportedly has potential to be used in BASF's PPO herbicide tolerance trait system currently under development.
- 2. **2021-22:** Cyclopyranil (KY-1211) from Kyoyu Agri is a novel PPO-other herbicide under development for the control off grass and broad-leaved weeds in rice production. It also has a very good control effect on rosegrass, quinoa and amaranth in upland crops. The mode of action is assigned based on




structural similarity to pyraclonil. Peak sales are estimated to be around US\$50m.

- 3. **2025-2030**: Novel PPO herbicide anticipated for launch in 2025-30. Codeveloped with Sumitomo Chemical for use in corn, soybean, and F&V.
- 4. **2020:** Cyclopyrimorate (SW-065) from Mitsui Chemicals Agro features a novel mode of action indicated as being a homogentisate solanesyltransferase inhibitor. Weed spectrum is indicated as being for broad-leaved weeds and sedges in cereal and rice production.
- 5. **2021:** Bixlozone (F9600) from FMC is indicated to be a novel mode of action in cereals. Weed spectrum is indicated as being against broad-leaved weeds and grasses in cereal production as well as a range of other crops including canola, rice, cotton, sugarcane and F&V.
- 6. 2021-22: Cyclopyranil (KY-1211) from Kyoyu Agri is a novel PPO-other herbicide under development for the control of grass and broad-leaved weeds in rice production. It also has a very good control effect on rosegrass, quinoa and amaranth in upland crops. The mode of action is assigned based on structural similarity to pyraclonil. Peak sales are estimated to be around US\$50m..
- 7. **2023:** Tetflupyrolimet from FMC is a new herbicide with a novel mode of action, which was identified as being through the inhibition of DHO dehydrogenase in the de Novo pyrimidine biosynthesis pathway. Selectivity has been demonstrated in field trials when used in the production of both direct seeded indica rice and transplanted japonica rice. The ai controls herbicide resistant grass weeds in rice, whilst also having activity against some sedges and broad-leaved weeds. Peak sales are likely to be around US\$300m.
- 8. 2024: Dimesulfazet (NC-653) from Nissan Chemicals is a trifluoromethansulfonanilide and has the potential to be a very long chain fatty acid elongation inhibitor (VLCFAE-I) as trifluoromethansulfonanilides such as mefluidide and perfluidone have been reported to inhibit a very-long-chain fatty acid synthesis. The sulfonailide moiety could also indicate some structural relationship to benzofluor, cloransulam, diclosulam, dimesulfazet, florasulam, flumetsulam, metosulam, perfluidone, profluazol, pyrimisulfan and triafamone, which would indicate the possibility of an ALS inhibition modality. Launch is currently anticipated for 2024F in Japan, with peak sales likely around US\$25m.
- 9. **2025:** Epyrifenacil (S-3100) is a novel PPO herbicide under development by Sumitomo Chemicals targeted at corn,wheat, barley, rice, sorghum, soybean, cotton, sugar beet, peanut, sunflower, canola, flowers and ornamental vegetables against a wide range of broad-leaved weeds and grasses.
- 10. 2027: Beflubutamid (resolved) FMC-herbicide 2 single resolved isomer of FMC's beflubutamid, with claimed higher biological activity compared to racemic beflubutamid on key EU weed species. The ai is broad spectrum PDS-type herbicide for pre- and early post-emergence control of broad-leaf weeds and some grasses. The resolved form of beflubutamid is reported by the company to be a new mode of action for resistance management in several regions and segments. Likely to be positioned in rice, cereals, maize and soybean.




#### Insecticides- anaemic growth

Overall growth in global insecticides market has been at a1.3% CAGR over CY12-20. However, biological products is the fastest-growing segment in insecticides.



#### Diamides – fastest-growing chemical in insecticides segment >

Figure 25: Neonicotinoid, pyrethroid and diamides remain top 3 chemicals class within insecticides; biologicals are gaining importance but still their growth is nowhere near diamides





### **InCred** Equities


Figure 26: Over the last nine years, diamides has been a fastest growth area in insecticides - almost 80% of growth has been driven by diamides Neonicotinoid Pyrethroid Diamides Organophosphate Other Biological - Fermentation
 Benzoylurea Other IGR Acaricide Carbamatel Biological - Microbial Organochlorine Other-pyridinyl 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% CY12 CY13 CY14 CY15 CY16 CY17 CY18 CY19 CY20 SOURCES: INCRED RESEARCH, IHSMARKIT


Chemicals | India

Chemicals - Overall | January 31, 2022

## Within diamides, chlorantraniliprole is the fastest-growing insecticide $\blacktriangleright$

Diamides comprise chlorantraniliprole, flubendiamide, cyantraniliprole, tetrachlorantraniliprole, tetraniliprole, broflanilide and cyclaniliprole. Within these molecules, chlorantraniliprole sales crossed US\$1bn in CY15 and the rest are well below even a half billion-dollar mark. Tetraniliprole, broflanilide and cyclaniliprole are relatively new molecules with one-to-two years in market.





### Diamides segment is a candidate for faster future growth as well ➤

- The diamide segment grew by +14.7% to US\$2,391m in 2020. The fastestgrowing segment in 2020 was diamides, driven by FMC's chlorantraniliprole and cyantraniliprole as well as Bayer/Nihon Nohyaku Flubendiamide. Key to the segment's fast growth during the year has been FMC's successful new product launches and continued penetration of recent introductions, both by FMC and through a number of licencing deals with third parties such as Hokko, Syngenta and Dhanuka Agritech.
- 2. Chlorantraniliprole is also deemed to be one of the more effective ais against fall armyworm.



- 3. Both chlorantraniliprole and cyantraniliprole benefited from the continued recovery in Brazil during 2020, the single largest country market for the actives.
- 4. The increased adoption of seed treatment technologies in developing markets stands both as a current driver and future growth opportunity for diamides.
- 5. The class unique mode of action, excellent efficacy and the ongoing action against neonicotinoids continues to benefit this group of ais.
- 6. The ongoing use of diamides to control fall army worm is also a key for the success of this class in 2020.
- 7. The diamide class vastly outperformed the wider industry. In Asian rice markets, fall armyworm pressure is a major driver of growth, given that the class has been shown to be amongst the most efficacious classes for control of what is a particularly challenging infestation.

#### Diamides are a risk for sales growth of pyrethroids >

In the recent past, we have seen sporadic success of pyrethroids to control fall armyworm in China. However, chlorantraniliprole (also called rynaxypyr) is a better and proven chemical to control infestation of fall armyworm.

#### Multiple Indian companies are active in insecticides >

Approximately 30% of UPL's products fall in insecticide category. Heranba is present in pyrethroids, and PI Industries does CRAMS of chlorantraniliprole for FMC. Even UPL has started contract manufacturing of CRAMS. Hence, insecticides are very important for Indian companies.

### However, Indian companies are not present in fastest-growing diamides space ➤

While UPL and PI Industries are doing CRAMS for rynaxypyr, they are not manufacturing any diamides of their own. Dhanuka and other companies can buy rynaxypyr from other manufacturers and sell it as a formulation as well. However, sadly no Indian company has taken any lead here.



#### DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared for and is distributed by CGS-CIMB, Incred Research Services Private Limited (formerly known as by Earnest Innovation Partners Private Limited (hereinafter referred to as "IRSPL") pursuant to an arrangement between IRSPL and CGS-CIMB. IRSPL is not an affiliate of CGS-CIMB. IRSPL is held 76% by InCred Capital Wealth Portfolio Managers Private Limited and 24% by EIP Holdings Private Limited. IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000007793. Pursuant to a trademark agreement, IRSPL has adopted "InCred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. The term "CGS-CIMB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case except as otherwise stated herein, CGS-CIMB Securities International Pte. Ltd. and its affiliates, subsidiaries and related corporations This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation and remains subject to the "Restrictions on Distribution" set out below. If your status has changed or the distribution restrictions set out below impact your ability to receive this report please contact your usual CGS-CIMB representative.

By accepting this report, the recipient hereof represents and warrants that he is entitled to receive such report in accordance with the restrictions set forth below and agrees to be bound by the limitations contained herein (including the "Restrictions on Distributions" set out below). Any failure to comply with these limitations may constitute a violation of law and limit our ability to provide reports to you.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL or CGS-CIMB.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

Under the terms of the agreement between IRSPL and CGS-CIMB, IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. Neither IRSPL nor CGS-CIMB is under any obligation to update this report in the event of a material change to the information contained in this report. Neither IRSPL nor CGS-CIMB has any and will accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies and/or CGS-CIMB, its affiliates and related persons including China Galaxy International Financial Holdings Limited ("CGIFHL") and CIMB Group Sdn. Bhd. ("CIMBG") and their respective related corporations (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof. In particular, CGS-CIMB disclaims all responsibility and liability for the views and opinions set out in this report.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies and/or CGS-CIMB or their respective affiliates (including CGIFHL, CIMBG and their respective related corporations) or IRSPL and its affiliates/group companies.

By IRSPL producing this report for CGS-CIMB, IRSPL has confirmed to CGS-CIMB that the opinions expressed are based on information it believes to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request.

The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests. IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report



### InCred Equities

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

#### Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

#### **CGS-CIMB DISCLOSURES**

Country	CGS-CIMB Entity	Regulated by
Hong Kong	CGS-CIMB Securities (Hong Kong) Limited	Securities and Futures Commission Hong Kong
India	CGS-CIMB Securities (India) Private Limited	Securities and Exchange Board of India (SEBI)
Indonesia	PT CGS-CIMB Sekuritas Indonesia	Financial Services Authority of Indonesia
Malaysia	CGS-CIMB Securities Sdn. Bhd.	Securities Commission Malaysia
Singapore	CGS-CIMB Securities (Singapore) Pte. Ltd.	Monetary Authority of Singapore
South Korea	CGS-CIMB Securities (Hong Kong) Limited, Korea Branch	Financial Services Commission and Financial Supervisory Service
Thailand	CGS-CIMB Securities (Thailand) Co. Ltd.	Securities and Exchange Commission Thailand

#### Other Significant Financial Interests:

As of the end of 31st December 2021 immediately preceding the date of this report CGS-CIMB does not:

 (i) have a proprietary position in the securities (which may include but not be limited to shares, warrants, call warrants and/or any other derivatives) in the company(ies) covered in this report except for the following:

(a) Nil

- (ii) act as market maker or have assumed an underwriting commitment in securities of the company(ies) covered in this report except for the following:
  (a) Nil
- (iii) perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to the company(ies) covered in this report and/or solicit such investment, advisory or other services from the company(ies) covered in this report except for the following:

(a) Nil



CGS-CIMB, its affiliates, related corporations (including CGIFHL, CIMBG and their respective related corporations) and/or their respective directors, associates, connected parties and/or employees and/or IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

CGS-CIMB, its affiliates and related corporations (including CGIFHL, CIMBG and their respective related corporations) and/or IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part

This report does not purport to contain all the information that a prospective investor may require. Neither CGS-CIMB nor any of its affiliates (including CGIFHL, CIMBG and their related corporations) make any guarantee, representation or warranty, express or implied, as to the adequacy, accuracy, completeness, reliability or fairness of any such information and opinion contained in this report. Neither CGS-CIMB nor any of its affiliates nor their related persons (including CGIFHL, CIMBG and their related corporations) shall be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

This report is general in nature and has been prepared for information purposes only. It is intended for circulation amongst CGS-CIMB's and its affiliates' (including CGIFHL's, CIMBG's and their respective related corporations') clients generally and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. The information and opinions in this report are not and should not be construed or considered as an offer, recommendation or solicitation to buy or sell the subject securities, related investments or other financial instruments or any derivative instrument, or any rights pertaining thereto.

Investors are advised to make their own independent evaluation of the information contained in this report, consider their own individual investment objectives, financial situation and particular needs and consult their own professional and financial advisers as to the legal, business, financial, tax and other aspects before participating in any transaction in respect of the securities of company(ies) covered in this report. The securities of such company(ies) may not be eligible for sale in all jurisdictions or to all categories of investors.

The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report

#### Restrictions on Distributions

Australia: Despite anything in this report to the contrary, this research is prepared for and provided in Australia by CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited. This research is only available in Australia to persons who are "wholesale clients" (within the meaning of the Corporations Act 2001 (Cth) and is supplied solely for the use of such wholesale clients and shall not be distributed or passed on to any other person. You represent and warrant that if you are in Australia, you are a "wholesale client". This research is of a general nature only and has been prepared without taking into account the objectives, financial situation or needs of the individual recipient. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited do not hold, and are not required to hold an Australian financial services license. CGS-CIMB Securities (Singapore) Pte. Ltd. and CGS-CIMB Securities (Hong Kong) Limited rely on "passporting" exemptions for entities appropriately licensed by the Monetary Authority of Singapore (under ASIC Class Order 03/1102) and the Securities and Futures Commission in Hong Kong (under ASIC Class Order 03/1103).

**Canada**: This report has not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 – Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organization of Canada. For any research report distributed by CIBC, further disclosures related to CIBC conflicts of interest can be found at https://researchcentral.cibcwm.com.

**China**: For the purpose of this report, the People's Republic of China ("PRC") does not include the Hong Kong Special Administrative Region, the Macau Special Administrative Region or Taiwan. The distributor of this report has not been approved or licensed by the China Securities Regulatory Commission or any other relevant regulatory authority or governmental agency in the PRC. This report contains only marketing information. The distribution of this report is not an offer to buy or sell to any person within or outside PRC or a solicitation to any person within or outside of PRC to buy or sell any instruments described herein. This report is being issued outside the PRC to a limited number of institutional investors and may not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose.

**France**: Only qualified investors within the meaning of French law shall have access to this report. This report shall not be considered as an offer to subscribe to, or used in connection with, any offer for subscription or sale or marketing or direct or indirect distribution of financial instruments and it is not intended as a solicitation for the purchase of any financial instrument.

**Germany**: This report is only directed at persons who are professional investors as defined in sec 31a(2) of the German Securities Trading Act (WpHG). This publication constitutes research of a non-binding nature on the market situation and the investment instruments cited here at the time of the publication of the information.

The current prices/yields in this issue are based upon closing prices from Bloomberg as of the day preceding publication. Please note that neither the German Federal Financial Supervisory Agency (BaFin), nor any other supervisory authority exercises any control over the content of this report.

Hong Kong: This report is prepared for and distributed in Hong Kong by CGS-CIMB Securities (Hong Kong) Limited ("CHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities) and Type 4 (advising on securities) activities. Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact the Head of Sales at CHK. The views and opinions in this report are our own as of the date hereof and are subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. CHK has no obligation to update its



opinion or the information in this report.

This publication is strictly confidential and is for private circulation only to clients of CHK.

India: This report is prepared by IRSPL for and distributed in India by IRSPL or CGS-CIMB Securities (India) Private Limited ("CGS-CIMB India"), as the case may be. CGS-CIMB India is a subsidiary of CGS-CIMB Securities International Pte. Ltd. which is in turn is a 50:50 joint venture company of CGIFHL and CIMBG. The details of the members of the group of companies of CGS-CIMB can be found at www.cgs-cimb.com, CGIFHL at www.chinastock.com.hk/en/ACG/ContactUs/index.aspx and CIMBG at www.cimb.com/en/who-we-are.html. CGS-CIMB India is registered with the National Stock Exchange of India Limited and BSE Limited as a trading and clearing member ( under the Securities and Exchange Board of India (Stock Brokers and Sub-Brokers) Regulations, 1992. CGS-CIMB India is registered with SEBI (SEBI Registration Number: INZ000209135) as a Research Analyst (INH000000669) pursuant to the SEBI (Research Analysts) Regulations, 2014 ("Regulations").

By IRSPL producing this report for CGS-CIMB, IRSPL has confirmed to CGS-CIMB that the research analysts, strategists or economists principally responsible for the preparation of this report are segregated from the other activities of IRSPL and they have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues, client feedback and competitive factors. Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed or proposed to be performed by IRSPL, CGS-CIMB India or its affiliates.

This report does not take into account the particular investment objectives, financial situations, or needs of the recipients. It is not intended for and does not deal with prohibitions on investment due to law/jurisdiction issues etc. which may exist for certain persons/entities. Recipients should rely on their own investigations and take their own professional advice before investment.

CGS-CIMB India does not have actual / beneficial ownership of 1% or more securities of the subject company in this report, at the end of the month immediately preceding the date of publication of this report. However, since affiliates of CGS-CIMB India are engaged in the financial services business, they might have in their normal course of business financial interests or actual / beneficial ownership of one per cent or more in various companies including the subject company in this report.

CGS-CIMB India or its associates, may: (a) from time to time, have long or short position in, and buy or sell the securities of the subject company in this report; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company in this report or act as an advisor or lender/borrower to such company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

CGS-CIMB India and associates have not received any compensation for investment banking, merchant banking or brokerage services from the subject company mentioned in the report in the past 12 months.

CGS-CIMB India and associates have not managed or co-managed public offering of securities for the subject company mentioned in the report in the past 12 months.

Indonesia: This report is prepared for and distributed in Indonesia by PT CGS-CIMB Sekuritas Indonesia ("CGS-CIMB Indonesia"). The views and opinions in this report is prepared from data believed to be correct and reliable at the time of issue of this report and are subject to change. CGS-CIMB Indonesia has no obligation to update the opinion or the information in this report. This report is for private circulation only to clients of CGS-CIMB Indonesia. Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable Indonesian capital market laws and regulations.

This report is not an offer of securities in Indonesia. The securities referred to in this report have not been registered with the Financial Services Authority (Otoritas Jasa Keuangan) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market law and regulations.

**Ireland**: CGS-CIMB is not an investment firm authorised in the Republic of Ireland and no part of this document should be construed as CGS-CIMB acting as, or otherwise claiming or representing to be, an investment firm authorised in the Republic of Ireland.

**Malaysia:** This report is prepared for and distributed in Malaysia by CGS-CIMB Securities Sdn. Bhd. ("CGS-CIMB Malaysia") solely for the benefit of and for the exclusive use of our clients. Recipients of this report are to contact CGS-CIMB Malaysia, at Level 29, Menara Bumiputra-Commerce, No. 11, Jalan Raja Laut, 50350 Kuala Lumpur, Malaysia, in respect of any matters arising from or in connection with this report. CGS-CIMB Malaysia has no obligation to update, revise or reaffirm the opinion or the information in this report after the date of this report.

**New Zealand**: In New Zealand, this report is for distribution only to persons who are wholesale clients pursuant to section 5C of the Financial Advisers Act 2008.

**Singapore:** This report is prepared for and distributed in Singapore by CGS-CIMB Securities (Singapore) Pte Ltd ("CGS-CIMB Singapore"). CGS-CIMB Singapore is a capital markets services licensee under the Securities and Futures Act (Chapter 289). Accordingly, it is exempted from the requirement to hold a financial adviser's licence under the Financial Advisers Act, Cap 110 ("FAA") for advising on investment products, by issuing or promulgating research analyses or reports, whether in electronic, print or other form. CGS-CIMB Singapore is subject to the applicable rules under the FAA unless it is able to avail itself to any prescribed exemptions.

Recipients of this report are to contact CGS-CIMB Singapore, 50 Raffles Place, #16-02 Singapore Land Tower, Singapore in respect of any matters arising from, or in connection with this report. CGS-CIMB Singapore has no obligation to update the opinion or the information in this report. This publication is strictly confidential and is for private circulation only. If you have not been sent this report by CGS-CIMB Singapore directly, you may not rely, use or disclose to anyone else this report or its contents.

If the recipient of this report is not an accredited investor, expert investor or institutional investor, CGS-CIMB Singapore accepts legal responsibility for the contents of the report without any disclaimer limiting or otherwise curtailing such legal responsibility. If the recipient is an accredited investor, expert investor or institutional investor, the recipient is deemed to acknowledge that CGS-CIMB Singapore is exempt from certain requirements under the FAA and its attendant regulations, and as such, is exempt from complying with the following:

(a) Section 25 of the FAA (obligation to disclose product information);

(b) Section 27 of the FAA (duty not to make recommendation with respect to any investment product without having a reasonable basis where you may be reasonably expected to rely on the recommendation);



(c) MAS Notice on Information to Clients and Product Information Disclosure [Notice No. FAA-N03];

(d) MAS Notice on Recommendation on Investment Products [Notice No. FAA-N16];

(e) Section 36 of the FAA (obligation on disclosure of interest in specified products); and

(f) any other laws, regulations, notices, directive, guidelines, circulars and practice notes which relates to the above, to the extent permitted by applicable laws, as may be amended from time to time, and any other laws, regulations, notices, directive, guidelines, circulars, and practice notes as we may notify you from time to time. In addition, the recipient who is an accredited investor, expert investor or institutional investor acknowledges that as CGS-CIMB Singapore is exempt from Section 27 of the FAA, the recipient will also not be able to file a civil claim against CGS-CIMB Singapore for any loss or damage arising from the recipient's reliance on any recommendation made by CGS-CIMB Singapore which would otherwise be a right that is available to the recipient under Section 27 of the FAA.

CGS-CIMB Singapore, its affiliates and related corporations, their directors, associates, connected parties and/or employees may own or have positions in specified products of the company(ies) covered in this report or any specified products related thereto and may from time to time add to or dispose of, or may be materially interested in, any such specified products. Further, CGS-CIMB Singapore, its affiliates and its related corporations do and seek to do business with the company(ies) covered in this report and may from time to time act as market maker or have assumed an underwriting commitment in specified products of such company(ies), may sell them to or buy them from customers on a principal basis and may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) as well as solicit such investment, advisory or other services from any entity mentioned in this report.

As of CGS-CIMB Singapore does not have a proprietary position in the recommended specified products in this report.

CGS-CIMB Singapore makes a market on the specified products.

CGS-CIMB Singapore does not make a market on other specified products mentioned in the report.

**South Korea:** This report is prepared for and distributed in South Korea by CGS-CIMB Securities (Hong Kong) Limited, Korea Branch ("CGS-CIMB Korea") which is licensed as a cash equity broker, and regulated by the Financial Services Commission and Financial Supervisory Service of Korea. In South Korea, this report is for distribution only to professional investors under Article 9(5) of the Financial Investment Services and Capital Market Act of Korea ("FSCMA").

**Spain**: This document is a research report and it is addressed to institutional investors only. The research report is of a general nature and not personalised and does not constitute investment advice so, as the case may be, the recipient must seek proper advice before adopting any investment decision. This document does not constitute a public offering of securities.

CGS-CIMB is not registered with the Spanish Comision Nacional del Mercado de Valores to provide investment services.

Sweden: This report contains only marketing information and has not been approved by the Swedish Financial Supervisory Authority. The distribution of this report is not an offer to sell to any person in Sweden or a solicitation to any person in Sweden to buy any instruments described herein and may not be forwarded to the public in Sweden.

**Switzerland**: This report has not been prepared in accordance with the recognized self-regulatory minimal standards for research reports of banks issued by the Swiss Bankers' Association (Directives on the Independence of Financial Research).

Thailand: This report is prepared for and distributed in Thailand by CGS-CIMB Securities (Thailand) Co. Ltd. ("CGS-CIMB Thailand") based upon sources believed to be reliable (but their accuracy, completeness or correctness is not guaranteed). The statements or expressions of opinion herein were arrived at after due and careful consideration for use as information for investment. Such opinions are subject to change without notice and CGS-CIMB Thailand has no obligation to update its opinion or the information in this report.

CGS-CIMB Thailand may act or acts as Market Maker, and issuer and offerer of Derivative Warrants and Structured Note which may have the following securities as its underlying securities. Investors should carefully read and study the details of the derivative warrants in the prospectus before making investment decisions.

AAV, ACE, ADVANC, AEONTS, AMATA, AOT, AP, BAM, BANPU, BBL, BCH, BCP, BCPG, BDMS, BEC, BEM, BGRIM, BH, BJC, BTS, CBG, CENTEL, CHG, CK, CKP, COM7, CPALL, CPF, CPN, CRC, DELTA, DOHOME, DTAC, EA, EGCO, ESSO, GLOBAL, GPSC, GULF, GUNKUL, HANA, HMPRO, ICHI, INTUCH, IRPC, IVL, JAS, JMART, JMT, KBANK, KCE, KKP, KTB, KTC, LH, MAJOR, MEGA, MINT, MTC, NRF, OR, ORI, OSP, PLANB, PRM, PSL, PTG, PTL, PTT, PTTEP, PTTGC, QH, RATCH, RBF, RS, SAWAD, SCB, SCC, SCGP, SINGER, SPALI, SPRC, STA, STEC, STGT, SUPER, SYNEX, TASCO, TCAP, THANI, TISCO, TKN, TOP, TQM, TRUE, TTB, TU, TVO, VGI, WHA

#### Corporate Governance Report:

The disclosure of the survey result of the Thai Institute of Directors Association ("IOD") regarding corporate governance is made pursuant to the policy of the Office of the Securities and Exchange Commission. The survey of the IOD is based on the information of a company listed on the Stock Exchange of Thailand and the Market for Alternative Investment disclosed to the public and able to be accessed by a general public investor. The result, therefore, is from the perspective of a third party. It is not an evaluation of operation and is not based on inside information.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. CGS-CIMB Thailand does not confirm nor certify the accuracy of such survey result.

Score Range:	90 - 100	80 – 89	70 - 79	Below 70	No Survey Result
Description:	Excellent	Very Good	Good	N/A	N/A



United Arab Emirates: The distributor of this report has not been approved or licensed by the UAE Central Bank or any other relevant licensing authorities or governmental agencies in the United Arab Emirates. This report is strictly private and confidential and has not been reviewed by, deposited or registered with UAE Central Bank or any other licensing authority or governmental agencies in the United Arab Emirates. This report is being issued outside the United Arab Emirates to a limited number of institutional investors and must not be provided to any person other than the original recipient and may not be reproduced or used for any other purpose. Further, the information contained in this report is not intended to lead to the sale of investments under any subscription agreement or the conclusion of any other contract of whatsoever nature within the territory of the United Arab Emirates.

**United Kingdom and European Economic Area (EEA)**: In the United Kingdom and European Economic Area, this material is prepared for and being distributed by CGS-CIMB Securities (UK) Limited ("CGS-CIMB UK"). CGS-CIMB UK is authorized and regulated by the Financial Conduct Authority and its registered office is at 27 Knightsbridge, London, SW1X7YB. The material distributed by CGS-CIMB UK has been prepared in accordance with CGS-CIMB's policies for managing conflicts of interest arising as a result of publication and distribution of this material. This material is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of CGS-CIMB UK; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (c) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc") of the Order; (d) are outside the United Kingdom subject to relevant regulation in each jurisdiction, material(all such persons together being referred to as "relevant persons"). This material is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

This material is categorised as non-independent for the purposes of CGS-CIMB UK and therefore does not provide an impartial or objective assessment of the subject matter and does not constitute independent research. Consequently, this material has not been prepared in accordance with legal requirements designed to promote the independence of research and will not be subject to any prohibition on dealing ahead of the dissemination of research. Therefore, this material is considered a marketing communication.

**United States**: This report is prepared for and distributed in the United States of America by CGS-CIMB Securities (USA) Inc, a U.S. registered brokerdealer and an affiliate of CGS-CIMB Securities Sdn. Bhd., CGS-CIMB Securities (Singapore) Pte Ltd, PT CGS-CIMB Sekuritas Indonesia, CGS-CIMB Securities (Thailand) Co. Ltd, CGS-CIMB Securities (Hong Kong) Limited and CGS-CIMB Securities (India) Private Limited, and is distributed solely to persons who qualify as "U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934. This communication is only for Institutional Investors whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major Institutional Investor must not rely on this communication. The delivery of this report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. CGS-CIMB Securities (USA) Inc, is a FINRA/SIPC member and takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc.

CGS-CIMB Securities (USA) Inc. has managed or co-managed a public offering of securities in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not managed or co-managed a public offering of any of the securities mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. has received compensation for investment banking services in the past 12 months.

CGS-CIMB Securities (USA) Inc. has not received compensation for investment banking services from any of the company mentioned in the past 12 months.

CGS-CIMB Securities (USA) Inc. expects to receive or intend to seek compensation for investment banking services within the next 3 months.

CGS-CIMB Securities (USA) Inc. neither expects to receive nor intends to seek compensation for investment banking services from any of the company mentioned within the next 3 months.

As of the end of the month immediately preceding the date of publication of this report, CGS-CIMB Securities (USA) Inc. beneficially owns 1% or more of any class of common equity securities.

**United States Third-Party Disclaimer**: If this report is distributed in the United States of America by Raymond James & Associates, Inc ("RJA"), this report is third-party research prepared for and distributed in the United States of America by RJA pursuant to an arrangement between RJA and CGS-CIMB Securities International Pte. Ltd. ("CGS-CIMB"). CGS-CIMB is not an affiliate of RJA. This report is distributed solely to persons who qualify as "U.S. Institutional Investors" or as "Major U.S. Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934, as amended. This communication is only for U.S. Institutional Investors or Major U.S. Institutional Investor whose ordinary business activities involve investing in shares, bonds, and associated securities and/or derivative securities and who have professional experience in such investments. Any person who is not a U.S. Institutional Investor or Major U.S. Institutional Investor must not rely on this communication. The delivery of this report to any person in the U.S. is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein. If you are receiving this report in the U.S from RJA, a FINRA/SIPC member, it takes responsibility for the content of this report. For further information or to place an order in any of the above-mentioned securities please contact a registered representative of CGS-CIMB Securities (USA) Inc. or RJA. <u>https://raymondjames.com/InternationalEquityDisclosures</u>

**Other jurisdictions:** In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is only for distribution to professional, institutional, or sophisticated investors as defined in the laws and regulations of such jurisdictions.



Chemicals | India Chemicals - Overall | January 31, 2022

Corporate Governance Report of Thai Listed Companies (CGR). CG Rating by the Thai Institute of Directors Association (Thai IOD) in 2021, Anti-Corruption 2021

ADVANC - Excellent, Certified, AMATA - Excellent, Certified, ANAN - Excellent, n/a, AOT - Excellent, n/a, AP - Excellent, Certified, ASP - Excellent, n/a, AWC - Excellent, Declared, AU - Good, n/a, BAM - Very Good, Certified, BAY - Excellent, Certified, BBL - Excellent, Certified, BCH - Very Good, Certified, BCP - Excellent, Certified, BCPG - Excellent, Certified, BDMS - Excellent, n/a, BEAUTY - Good, n/a, BEM - Excellent, n/a BH -Good, n/a, BJC - Very Good, n/a, BLA - Very Good, Certified, BTS - Excellent, Certified, CBG - Very Good, n/a, CCET - n/a, n/a, CENTEL -Excellent, Certified, CHAYO - Very Good, n/a, CHG - Very Good, n/a, CK - Excellent, n/a, COM7 - Excellent, Certified, CPALL - Excellent, Certified, CPF - Excellent, Certified, CPN - Excellent, Certified, CPNREIT - n/a, n/a, CRC - Excellent, Declared, DELTA - Excellent, Certified, DDD - Excellent, n/a, DIF - n/a, n/a, DOHOME - Very Good, Declared, DREIT - n/a, n/a, DTAC - Excellent, Certified, ECL - Excellent, Certified, EGCO - Excellent, Certified, EPG - Excellent, Certified, ERW - Very Good, Certified, GFPT - Excellent, Certified, GGC - Excellent, Certified, GLOBAL - Excellent, n/a, HANA - Excellent, Certified, HMPRO - Excellent, Certified, HUMAN - Good, n/a, ICHI - Excellent, Certified, III - Excellent, Declared, INTUCH -Excellent, Certified, IRPC - Excellent, Certified, ITD - Very Good, n/a, IVL - Excellent, Certified, JASIF - n/a, n/a, JKN - n/a, Certified, JMT - Very Good, n/a, KBANK - Excellent, Certified, KCE - Excellent, Certified, KEX - Very Good, Declared, KKP - Excellent, Certified, KSL - Excellent, Certified, KTB - Excellent, Certified, KTC - Excellent, Certified, LH - Excellent, n/a, LPN - Excellent, Certified, M - Very Good, Certified, MAKRO - Excellent, Certified, MC - Excellent, Certified, MEGA - Very Good, n/a, MINT - Excellent, Certified, MTC - Excellent, Certified, NETBAY - Very Good, n/a, NRF - Very Good, Declared, OR - Excellent, n/a, ORI - Excellent, Certified, OSP - Excellent, n/a, PLANB - Excellent, Certified, PRINC - Very Good, Certified, PR9 - Excellent, Declared, PSH - Excellent, Certified, PTT - Excellent, Certified, PTTEP - Excellent, n/a, PTTGC - Excellent, Certified, QH - Excellent, Certified, RAM - n/a, n/a, RBF - Very Good, n/a, RS - Excellent, Declared, RSP - Good, n/a, S - Excellent, n/a, SAK - Very Good, Declared, SAPPE - Very Good, Certified, SAWAD - Very Good, n/a, SCB - Excellent, Certified, SCC - Excellent, Certified, SCGP - Excellent, Declared, SECURE - n/a, n/a, SHR - Excellent, n/a, SIRI - Excellent, Certified, SPA - Very Good, n/a, SPALI - Excellent, Certified, SPRC - Excellent, Certified, SSP - Good, Certified, STEC - Excellent, n/a, SVI - Excellent, Certified, SYNEX - Very Good, Certified, TCAP - Excellent, Certified, THANI - Excellent, Certified, TIDLOR - n/a, Certified TISCO - Excellent, Certified, TKN - Very Good, n/a, TOP - Excellent, Certified, TRUE - Excellent, Certified, TTB - Excellent, Certified, TU - Excellent, Certified, TVO - Excellent, Certified, VGI - Excellent, Certified, WHA - Excellent, Certified, WHART - n/a, n/a, WICE - Excellent, Certified, WORK - Good, n/a.

- CG Score 2021 from Thai Institute of Directors Association (IOD)

- Companies participating in Thailand's Private Sector Collective Áction Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of August 5, 2021) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.

Recommendation Fran	nework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	n of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net ock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.